Skip to main content

Table 2 Clinical characteristics of study cohorts at the start of first-line therapy

From: Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States

Characteristics

Overall

N = 5807

RET+

N = 46

RET-

N = 5761

RET+ vs RET-

P value*

Body weight (kg)

 Mean (Sd)

75.7 (18.8)

74.9 (16.2)

75.7 (18.8)

0.81

 Median (IQR)

73.7 (62.1, 86.4)

70.1 (62.8, 86.4)

73.8 (62.1, 86.4)

 

BMI category, n (%)

 Underweight

302 (5.4)

2 (4.7)

300 (5.4)

0.82

 Normal

2203 (39.1)

20 (46.5)

2183 (39.0)

 

 Overweight

1843 (32.7)

13 (30.2)

1830 (32.7)

 

 Obese

1289 (22.9)

8 (18.6)

1281 (22.9)

 

 Missing/Unknown

170

3

167

 

Stage at initial diagnosis, n (%)

 Stage I

486 (8.5)

3 (6.5)

483 (8.6)

0.34

 Stage II

335 (5.9)

0 (0.0)

335 (5.9)

 

 Stage III

1154 (20.3)

9 (19.6)

1145 (20.3)

 

 Stage IV

3714 (65.3)

34 (73.9)

3680 (65.2)

 

 Missing/Unknown

118

0

118

 

Histology, n (%)

 Non-squamous

4437 (79.6)

45 (100.0)

4392 (79.4)

< 0.0001

 Squamous

1138 (20.4)

0 (0.0)

1138 (20.6)

 

 Missing/Unknown

232

1

231

 

Smoking status, n (%)

 Smoking history

4720 (81.5)

17 (37.0)

4703 (81.9)

< 0.0001

 No smoking history

1071 (18.5)

29 (63.0)

1042 (18.1)

 

 Missing/Unknown

16

0

16

 

ECOG performance status, n (%)

 0

1438 (33.8)

19 (61.3)

1419 (33.6)

0.02

 1

2088 (49.1)

9 (29.0)

2079 (49.2)

 

 2

595 (14.0)

2 (6.5)

593 (14.0)

 

 3+

136 (3.2)

1 (3.2)

135 (3.2)

 

 Missing/Unknown

1550

15

1535

 

RET fusion partner

 KIF5B

–

29 (63.0)

–

–

 CCDC6

–

11 (23.9)

–

 

 NCOA4

–

3 (6.5)

–

 

 Otherd

–

3 (6.5)

–

 

EGFR positive, n (%)

 Yes

447 (18.8)

3 (8.6)

444 (18.9)

0.19

 No

1936 (81.2)

32 (91.4)

1904 (81.1)

 

 Missing/Unknown

3424

11

3413

 

ALK positive, n (%)

 Yes

80 (3.7)

0 (0.0)

80 (3.8)

0.64

 No

2086 (96.3)

34 (100.0)

2052 (96.3)

 

 Missing/Unknown

3641

12

3629

 

KRAS positive, n (%)

 Yes

233 (24.6)

0 (0.0)

233 (25.0)

0.05

 No

714 (75.4)

13 (100.0)

701 (75.1)

 

 Missing/Unknown

4860

33

4827

 

ROS1 positive, n (%)

 Yes

16 (1.2)

0 (0.00)

16 (1.2)

1.0

 No

1310 (98.8)

19 (100.0)

1291 (98.8)

 

 Missing/Unknown

4481

27

4454

 

BRAF positive, n (%)

 Yes

42 (4.9)

0 (0.0)

42 (4.9)

1.0

 No

820 (95.1)

7 (100.0)

813 (95.1)

 

 Missing/Unknown

4945

39

4906

 

MSI status, n (%)

 MSI high

7 (0.2)

0 (0.0)

7 (0.3)

1.0

 MSI stable

2849 (99.3)

22 (100.0)

2827 (99.3)

 

 MSI intermediate

13 (0.5)

0 (0.0)

13 (0.5)

 

 Missing/Unknown

2938

24

2914

 

PD-L1 expressiona, n (%)

 Positive (≥ 1%)

1206 (47.4)

15 (68.2)

1191 (47.2)

0.06

 Negative

1337 (52.6)

7 (31.8)

1330 (52.8)

 

 Missing/Unknown

3264

24

3240

 

FMI PD-L1 expressionb, n (%)

 High Positive (≥50%)

390 (31.2)

2 (28.6)

388 (31.2)

0.21

 Low Positive (1–49%)

353 (28.2)

4 (57.1)

349 (28.1)

 

 Negative

507 (40.6)

1 (14.3)

506 (40.7)

 

 Missing/Unknown

4557

39

4518

 

Time from metastatic diagnosis to FMI testc, days

 Mean (Sd)

86.7 (427.1)

135.9 (480.4)

86.3 (426.6)

0.43

 Median (IQR)

0 (0.0, 49.0)

1.5 (0.0, 441.0)

0 (0.0, 49.0)

 

Adrenal metastases, n (%)

 Yes

657 (11.3)

3 (6.5)

654 (11.4)

0.48

 Not reported

5150 (88.7)

43 (93.5)

5107 (88.7)

.

Bone metastases, n (%)

 Yes

2018 (34.8)

21 (45.7)

1997 (34.7)

0.12

 Not reported

3789 (65.3)

25 (54.4)

3764 (65.3)

 

Brain metastases, n (%)

 Yes

1156 (19.9)

9 (19.6)

1147 (19.9)

1.0

 Not reported

4651 (80.1)

37 (80.4)

4614 (80.1)

 

Distant lymph node metastases, n (%)

 Yes

808 (13.9)

7 (15.2)

801 (13.9)

0.83

 Not reported

4999 (86.1)

39 (84.8)

4960 (86.1)

 

Liver metastases, n (%)

 Yes

697 (12.0)

13 (28.3)

684 (11.9)

0.0007

 Not reported

5110 (88.0)

33 (71.7)

5077 (88.1)

 

Other metastases, n (%)

 Yes

4176 (71.9)

27 (58.7)

4149 (72.0)

0.05

 Not reported

1631 (28.1)

19 (41.3)

1612 (28.0)

 
  1. *Missing values are not included in the statistical comparison between cohorts; comparisons based on t-test for continuous variables and Chi square test for categorical variables; Fisher’s exact test was used for cells with frequencies < 5
  2. aAs reported in the EHR or FMI test results available at the time of initiation of therapy
  3. bLimited to FMI test results available at the time of initiation of therapy
  4. cNegative days (ie, tests prior to advanced diagnosis) set to zero
  5. dOther fusions included TRIM24, GAS2 and FRD4A
  6. RET rearranged during transfection; Sd standard deviation; IQR interquartile range; BMI body mass index; ECOG Eastern Cooperative Oncology Group; FMI Foundation Medicine, Inc.; EHR electronic health record; EGFR epidermal growth factor receptor; PD-L1 programmed death ligand 1; MSI microsatellite instability; ALK anaplastic lymphoma kinase; KRAS Kirsten rat sarcoma viral oncogene homolog; ROS1 ROS proto-oncogene 1; BRAF v-raf murine sarcoma viral oncogene homolog B